Particulate contamination in selected parenteral drugs

Area of Science:

• Pharmaceutical Science
• Drug Quality Control
• Particulate Matter Analysis

Background:

• Particulate contamination in parenteral drugs is a critical concern for patient safety.
• Previous studies have indicated variability in particulate loads across different drug formulations.
• Understanding the sources and levels of contamination is essential for improving drug manufacturing.

Purpose of the Study:

• To quantify and characterize particulate contamination in five frequently prescribed drugs.
• To investigate the correlation between drug manufacturing processes and observed particulate levels.
• To assess the potential need for in-line filtration in specific patient populations.

Main Methods:

• Samples of five common drugs were collected using sterile techniques in a laminar flow workbench.
• Particulate contamination was assessed on dry sample filters using microscopy at 50x and 100x magnification.
• Particles were categorized by size (fibers, >100 microns, 51-100 microns, 25-50 microns, 10-24 microns).

Main Results:

• Significant variability in particulate contamination was observed among the studied drugs.
• Particulate counts demonstrated a correlation with the drug manufacturing process.
• Bulk powders exhibited the highest contamination, followed by lyophilized powders, and then stable solutions.

Conclusions:

• Drug manufacturing processes directly influence particulate contamination levels.
• In-line filters may offer a protective measure for selected patients pending further clinical significance evaluation.
• Improvements in manufacturing processes are recommended to reduce drug particulate contamination.